Pioneering work using preclinical models of myeloproliferative diseases led to an expansion of the role of LSD1 inhibition in these diseases, where it was shown to prolong survival in murine disease models by reducing the clone size.136. This evidence concerns the gene KDM1A and myeloproliferative disorder.